|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| C07K 16/28 | (2006.01) | ||
| A61P 17/06 | (2006.01) |
| (11) | Number of the document | 3295957 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17195530.5 |
| Date of filing the European patent application | 2011-01-12 | |
| (97) | Date of publication of the European application | 2018-03-21 |
| (45) | Date of publication and mention of the grant of the patent | 2019-08-07 |
| (46) | Date of publication of the claims translation | 2020-01-27 |
| (30) | Number | Date | Country code |
| 295387 P | 2010-01-15 | US | |
| 422059 P | 2010-12-10 | US |
| (72) |
LIU, Dingjiang, US
HUANG, Holly Zhuohong, US
MARTIN, David Andrew, US
RUSSELL, Christopher Boyd, US
SALINGER, David H., US
BAUMGARTNER, Scott Walter, US
ENDRES, Christopher J., US
|
| (73) |
Amgen K-A, Inc.,
One Amgen Center Drive, Thousand Oaks, CA 91320,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Anti-IL-17RA antikūno kompozicija ir terapiniai režimai, skirti psoriazės gydymui |
| ANTI IL-17RA ANTIBODY FORMULATION AND THERAPEUTIC REGIMENS FOR TREATING PSORIASIS |
| Payment date | Validity (years) | Amount | |
| 2025-01-06 | 15 | 289.00 EUR |
| 2026-01-12 |